Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Taro Pharmaceutical Indus (NYSE:TARO) reported its Q1 earnings results on Wednesday, July 27, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Taro Pharmaceutical Indus missed estimated earnings by 56.47%, reporting an EPS of $0.37 versus an estimate of $0.85.
Revenue was up $9.55 million from the same period last year.
Last quarter the company missed on EPS by $0.15 which was followed by a 3.89% increase in the share price the next day.
Here's a look at Taro Pharmaceutical Indus's past performance:
Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
---|---|---|---|---|
EPS Estimate | 0.88 | 0.91 | 1.02 | 0.84 |
EPS Actual | 0.73 | 0.70 | 0.66 | 1.09 |
Revenue Estimate | 147.01M | 142.22M | 153.23M | 137.23M |
Revenue Actual | 143.26M | 139.00M | 131.99M | 147.11M |
To track all earnings releases for Taro Pharmaceutical Indus visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: TARO